PT  - JOURNAL ARTICLE
AU  - Sun, Kaiyuan
AU  - Bhiman, Jinal N.
AU  - Tempia, Stefano
AU  - Kleynhans, Jackie
AU  - Madzorera, Vimbai Sharon
AU  - Mkhize, Qiniso
AU  - Kaldine, Haajira
AU  - McMorrow, Meredith L
AU  - Wolter, Nicole
AU  - Moyes, Jocelyn
AU  - Carrim, Maimuna
AU  - Martinson, Neil A
AU  - Kahn, Kathleen
AU  - Lebina, Limakatso
AU  - du Toit, Jacques D.
AU  - Mkhencele, Thulisa
AU  - von Gottberg, Anne
AU  - Viboud, Cécile
AU  - Moore, Penny L.
AU  - Cohen, Cheryl
AU  - ,
TI  - SARS-CoV-2 correlates of protection from infection against variants of concern
AID  - 10.1101/2024.05.28.24308095
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.28.24308095
4099  - http://medrxiv.org/content/early/2024/06/07/2024.05.28.24308095.short
4100  - http://medrxiv.org/content/early/2024/06/07/2024.05.28.24308095.full
AB  - Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic COVID-19 and severe disease. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against SARS-CoV-2 immune-escape variants. In this study, we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates of protection (CoPs) against Delta and Omicron BA.1/2 wave infections, in rural and urban household cohorts in South Africa. We find that, in the Delta wave, anti-D614G nAbs mediate 37% (95%CI 34% – 40%) of the total protection against infection conferred by prior exposure to SARS-CoV-2, and that protection decreases with waning immunity. In contrast, anti-Omicron BA.1 nAbs mediate 11% (95%CI 9 – 12%) of the total protection against Omicron BA.1/2 wave infections, due to Omicron’s neutralization escape. These findings underscore that CoPs mediated through nAbs are variant-specific, and that boosting of nAbs against circulating variants might restore or confer immune protection lost due to nAb waning and/or immune escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural infection cannot be fully explained by serum nAbs alone. Measuring these and other immune markers including T-cell responses, both in the serum and in other compartments such as the nasal mucosa, may be required to comprehensively understand and predict immune protection against SARS-CoV-2.Competing Interest StatementCC has received grant support from Sanofi Pasteur, US CDC, the Bill & Melinda Gates Foundation, the Taskforce for Global Health, Wellcome Trust and the South African Medical Research Council. AvG has received grant support from Sanofi Pasteur, Pfizer related to pneumococcal vaccine, CDC and the Bill & Melinda Gates Foundation. NW reports grants from Sanofi Pasteur and the Bill & Melinda Gates Foundation. NAM has received a grant to his institution from Pfizer to conduct research in patients with pneumonia and from Roche to collect specimens to assess a novel TB assay. JM has received grant support from Sanofi Pasteur. The remaining authors declare no competing interestsFunding StatementThis work was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service and the U.S. Centers for Disease Control and Prevention [cooperative agreement number: 6 U01IP001048] and Wellcome Trust (grant number 221003/Z/20/Z) in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom. PLM and JNB are supported by the Bill and Melinda Gates Foundation through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program (INV-030570) and receive funding from the Wellcome Trust (226137/Z/22/Z). PLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa and the SA Medical Research Council SHIP program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PHIRST-C protocol was approved by the University of Witwatersrand Human Research Ethics Committee (Reference 150808) and the U.S. Centers for Disease Control and Prevention's Institutional Review Board relied on the local review (#6840). The protocol was registered on clinicaltrials.gov on 6 August 2015 and updated on 30 December 2020 (https://clinicaltrials.gov/ct2/show/NCT02519803). Participants receive grocery store vouchers of ZAR50 (USD 3) per visit to compensate for time required for specimen collection and interview. All participants provided informed consent for study participation. For minors, consent was obtained from the parent or guardian.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes